Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT06503939

Etiology Analysis of Chronic Cough After COVID-19 Infection and Research on the Efficacy of ICS or ICS/LABA

Status
Enrolling By Invitation
Phase
Study type
Observational
Enrollment
600 (estimated)
Sponsor
Xiangya Hospital of Central South University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study collected 600 patients, evaluated whether patients had airway hyperreactivity, airway inflammation, specific types and allergic reactions, comprehensively analyzed and classified the causes of chronic cough in patients, and evaluated and compared the improvement of cough symptoms and quality of life after ICS or ICS/LABA treatment.

Detailed description

The subjects of this study were patients with chronic cough who were admitted to the Department of Respiratory and Critical Care Medicine, Xiangya Hospital, Central South University from September 1, 2023 to December 31, 2024. Patients are registered if they meet all of the following criteria: (1) ≥18 years of age; (2) A clear history of COVID-19 infection with a positive nucleic acid or antigen test before chronic cough;(3) Persistent cough for more than 8 weeks after the acute phase of COVID-19 infection has disappeared; (4) Chest X-ray and/or chest CT without significant evidence of lung disease; (5) No history of chronic cough (\>8 weeks) prior to COVID-19 infection. Patients who met any of the following criteria were excluded: (1) Patients refused pulmonary function, blood tests; (2) The patient has previously been diagnosed with respiratory diseases with cough as one of the main symptoms, including cough variant asthma, allergic bronchitis, eosinophilic bronchitis, gastroesophageal reflux disease, chronic obstructive pulmonary disease, chronic bronchitis, bronchiectasis, interstitial lung disease, pulmonary/tracheobronchial tuberculosis, etc.; (3) Patients who are pregnant or breastfeeding; (4) The patient's medical records are incomplete; (5) Patients lost to follow-up.

Conditions

Timeline

Start date
2023-09-01
Primary completion
2024-12-31
Completion
2024-12-31
First posted
2024-07-16
Last updated
2024-07-16

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06503939. Inclusion in this directory is not an endorsement.